Horizon Pharma (NASDAQ:HZNP) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.17, Bloomberg Earnings reports. The business had revenue of $302.84 million for the quarter, compared to the consensus estimate of $275.51 million. Horizon Pharma had a negative net margin of 45.06% and a positive return on equity of 16.97%. The business’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.41 EPS.
Horizon Pharma traded down $0.28, reaching $20.63, during mid-day trading on Friday, Marketbeat Ratings reports. The company had a trading volume of 22,236 shares, compared to its average volume of 1,149,569. The company has a debt-to-equity ratio of 2.17, a current ratio of 1.56 and a quick ratio of 1.50. The company has a market capitalization of $3.00 billion, a P/E ratio of 17.64, a P/E/G ratio of 1.09 and a beta of 1.43. Horizon Pharma has a 12 month low of $11.17 and a 12 month high of $21.10.
Several analysts have commented on the stock. BidaskClub upgraded shares of Horizon Pharma from a “buy” rating to a “strong-buy” rating in a research note on Friday. Jefferies Financial Group boosted their price target on shares of Horizon Pharma from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday. Mizuho reiterated a “buy” rating and issued a $18.00 price target on shares of Horizon Pharma in a research note on Wednesday. Piper Jaffray Companies restated a “buy” rating and set a $25.00 target price on shares of Horizon Pharma in a research report on Thursday. Finally, Cowen restated a “buy” rating and set a $25.00 target price on shares of Horizon Pharma in a research report on Thursday. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Horizon Pharma currently has a consensus rating of “Buy” and an average target price of $20.27.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
See Also: Diversification For Individual Investors
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.